Patents by Inventor Tohru Tanaka

Tohru Tanaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220331855
    Abstract: This structural member (W1) is manufactured using a structural member manufacturing device including: a first clamping part (10) having a first lower clamping member (11) and a second upper clamping member (12) disposed to face each other and capable of being opened and closed; a second clamping part (20) having a third lower clamping member (21) and a fourth upper clamping member (22) disposed to face each other corresponding to the first lower clamping member (11) and the second upper clamping member (12) and capable of being opened and closed; and clamping part driving means for allowing the first clamping part (10) and the second clamping part (20) to be relatively separated from each other while causing a position in an X-axis direction and a position in a Z-axis direction to correspond to each other.
    Type: Application
    Filed: September 25, 2020
    Publication date: October 20, 2022
    Applicant: NIPPON STEEL CORPORATION
    Inventors: Satoshi SHIRAKAMI, Yasuharu TANAKA, Koichi SATO, Shigeru YONEMURA, Tohru YOSHIDA
  • Patent number: 11421204
    Abstract: A stem cell removing method that certainly-removes an undifferentiated stem cell is provided. For this object, a cell group including a stem cell and a somatic cell performed differentiation induction is cultivated in culture medium composition including photosensitizer. Light of a specific wavelength is irradiated with the cell group, and the stem cell is removed, selectively. The stem cell is a pluripotent stem cell or a somatic stem cell. The pluripotent stem cell includes either an ES cell (Embryonic Stem Cell) or an iPS cell (induced Pluripotent Stem Cell). Also, somatic stem cell includes any one of a germ stem cell, a productive cell, a pluripotent stem cell and a stem cell having unipotency.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: August 23, 2022
    Assignees: REPROCELL INCORPORATED, SBI PHARMACEUTICALS CO., LTD.
    Inventors: Shunsuke Yoshida, Mitsuru Inamura, Tohru Tanaka, Hiroyuki Ishikawa, Hidenori Ito
  • Publication number: 20220249417
    Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.
    Type: Application
    Filed: February 28, 2022
    Publication date: August 11, 2022
    Inventors: Tohru Tanaka, Hidenori Ito, Ko Rii
  • Publication number: 20220246259
    Abstract: A lifestyle improvement specific measure presenting device includes a formulating unit which formulates a lifestyle improvement strategy, which is a behavioral strategy for a user for improving a predetermined lifestyle habit of the user, on the basis of information indicating the predetermined lifestyle habit, included in a predicted result of the future health condition of the user if the predetermined lifestyle habit is improved.
    Type: Application
    Filed: April 23, 2020
    Publication date: August 4, 2022
    Applicant: NEC Solution Innovators, Ltd.
    Inventors: Hirofumi TANAKA, Toshikazu TAJIRI, Tohru MIYAZAKI
  • Patent number: 11266619
    Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: March 8, 2022
    Assignees: SBI Pharmaceuticals Co., Ltd., National Center for Child Health and Development
    Inventors: Tohru Tanaka, Hidenori Ito, Ko Rii
  • Patent number: 11123320
    Abstract: Various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: September 21, 2021
    Assignees: SBI PHARMACEUTICALS, CO., LTD., NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY
    Inventors: Tohru Tanaka, Kiwamu Takahashi, Keiji Inoue, Motoaki Saito, Masayuki Tsuda, Hideo Fukuhara, Takahira Kuno, Shogo Shimizu
  • Publication number: 20200297674
    Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.
    Type: Application
    Filed: November 28, 2018
    Publication date: September 24, 2020
    Inventors: Tohru Tanaka, Hidenori Ito, Ko Rii
  • Publication number: 20200163917
    Abstract: various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.
    Type: Application
    Filed: May 21, 2018
    Publication date: May 28, 2020
    Inventors: Tohru TANAKA, Kiwamu TAKAHASHI, Keiji INOUE, Motoaki SAITO, Masayuki TSUDA, Hideo FUKUHARA, Takahira KUNO, Shogo SHIMIZU
  • Patent number: 10022345
    Abstract: The object of the present invention is to provide a hangover prophylactic and/or therapeutic agent. The present invention provides a hangover prophylactic and/or therapeutic agent comprising ALAs.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: July 17, 2018
    Assignee: SBI PHARMACEUTICALS CO., LTD.
    Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Satofumi Kawata
  • Publication number: 20180127726
    Abstract: A stem cell removing method that certainly-removes an undifferentiated stem cell is provided. For this object, a cell group including a stem cell and a somatic cell performed differentiation induction is cultivated in culture medium composition including photosensitizer. Light of a specific wavelength is irradiated with the cell group, and the stem cell is removed, selectively. The stem cell is a pluripotent stem cell or a somatic stem cell. The pluripotent stem cell includes either an ES cell (Embryonic Stem Cell) or an iPS cell (induced Pluripotent Stem Cell). Also, somatic stem cell includes any one of a germ stem cell, a productive cell, a pluripotent stem cell and a stem cell having unipotency.
    Type: Application
    Filed: April 6, 2016
    Publication date: May 10, 2018
    Applicants: REPROCELL INCORPORATED, SBI PHARMACEUTICALS CO., LTD.
    Inventors: Shunsuke YOSHIDA, Mitsuru INAMURA, Tohru TANAKA, Hiroyuki ISHIKAWA, Hidenori ITO
  • Publication number: 20180125805
    Abstract: The present invention addresses the problem of providing a prophylactic/therapeutic agent which is inexpensive, has little adverse side effects and is effective against persistent virus infections. A 5-aminolevulinic acid compound represented by the following formula (I) (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group or an aralkyl group) or a salt thereof can be used as a prophylactic and/or therapeutic agent for virus infections to prevent proliferation of viruses.
    Type: Application
    Filed: March 18, 2016
    Publication date: May 10, 2018
    Applicant: SBI Pharmaceuticals Co., Ltd.
    Inventors: Tohru TANAKA, Motowo NAKAJIMA, Takeshi HARA
  • Patent number: 9962350
    Abstract: It is intended to provide an in vitro culture medium that allows the in vitro culture of fertilized eggs to progress normally to the blastocyst stage without arresting the development thereof. The normal development rate of a fertilized egg is improved by using 5-aminolevulinic acids represented by the following formula (I) (wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group) or salts thereof as an agent for improving a normal development rate of a fertilized egg.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: May 8, 2018
    Assignees: SBI Pharmaceuticals Co., Ltd., Yamagata University
    Inventors: Tohru Tanaka, Motowo Nakajima, Kiwamu Takahashi, Osamu Nakajima
  • Patent number: 9937138
    Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: April 10, 2018
    Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.
    Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
  • Patent number: 9901558
    Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: February 27, 2018
    Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.
    Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
  • Patent number: 9895331
    Abstract: An object of the present invention is to provide a preventive and/or therapeutic agent for radiation damage that has a novel mechanism of action and can prevent and alleviate a wide range of symptoms of radiation damage for which no therapeutic measures have been available so far, and moreover, is highly safe to humans. A preventive and/or therapeutic agent for radiation damage comprising a compound represented by the following formula (I) such as 5-aminolevulinic acid (5-ALA) or a salt thereof as an active ingredient can be used to improve the survival rate, improve body weight reduction, and alleviate hematopoietic disorder: (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group).
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: February 20, 2018
    Assignees: The University of Tokyo, SBI Pharmaceuticals Co., Ltd.
    Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Hidenori Ito, Kiwamu Takahashi, Kouji Matsushima, Satoshi Ueha, Jun Abe
  • Patent number: 9772286
    Abstract: It is to provide a method for detecting urothelial cancer simply and with high accuracy. It is a method for detecting urothelial cancer comprising administering 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these to a test subject, collecting urine from the test subject, and detecting the presence of fluorescence or amount of fluorescence in the collected urine.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: September 26, 2017
    Assignees: SBI Pharmaceuticals Co., Ltd., National University Corporation Kochi University
    Inventors: Keiji Inoue, Taro Shuin, Mutsuo Furihata, Yoshihiko Hirao, Tohru Tanaka
  • Patent number: 9757357
    Abstract: It is intended to provide a therapeutic and/or diagnostic agent that can be used in photodynamic therapy (PDT) or photodynamic diagnosis (PDD) capable of utilizing infrared-spectrum light such as near-infrared light (NIR), infrared light, or far-infrared light, which attains a deep body penetration. The present invention provides a photodynamic therapeutic or diagnostic agent or a photodynamic therapeutic or diagnostic kit for cancer or infectious disease, comprising: a particle (e.g., a lanthanide particle) that emits upconversion luminescence by infrared-spectrum light such as near-infrared light having a wavelength of 0.7 ?m to 2.5 ?m; and a photosensitizer (e.g., porphyrin) or a 5-aminolevulinic acid group.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: September 12, 2017
    Assignees: Tokyo Institute of Technology, SBI Pharmaceuticals Co., Ltd.
    Inventors: Hideya Yuasa, Shun-ichiro Ogura, Kiwamu Takahashi, Katushi Inoue, Tohru Tanaka
  • Patent number: 9730904
    Abstract: A pharmaceutical composition which is different from an existing therapeutic agent of an adult disease, of a biochemical reaction-inhibiting type, and which action mechanism is to improve the basal metabolism, wherein the composition has no side effects, and does not generate drug resistance against adult disease; and a method for preventing/treating an adult disease by using the same.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: August 15, 2017
    Assignee: SBI Pharmaceuticals Co., Ltd.
    Inventor: Tohru Tanaka
  • Publication number: 20170202210
    Abstract: Provided is an organ preservation solution for use in transplantation, which is capable of effectively preventing the occurrence of ischemia-reperfusion injury. Prepared is an organ preservation solution comprising a mixture of the following components: (a) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, and D-glucose; (b) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, glycine, and D-glucose; (c) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, and D-glucose; or (d) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, an iron compound, and D-glucose.
    Type: Application
    Filed: February 24, 2015
    Publication date: July 20, 2017
    Inventors: Tohru TANAKA, Motowo NAKAJIMA, Urara OTA, Hidenori ITO, Ko RII
  • Patent number: 9707196
    Abstract: A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (I): R1—NHCH2COCH2CH2COOR2??(I) wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: July 18, 2017
    Assignees: SBI Pharmaceuticals Co., Ltd., National University Corporation Kochi University
    Inventors: Tohru Tanaka, Kyoko Tsuchiya, Masahiro Ishizuka, Motowo Nakajima, Hitoshi Nakagawa, Taro Shuin, Keiji Inoue, Hideo Fukuhara, Masayuki Tsuda, Mutsuo Furihata